Time course of moricizine's effect on signal-averaged and 12 lead electrocardiograms: insights into mechanism of action

Quinidine pharmacodynamics in patients with arrhythmia: effects of left ventricular function

OBJECTIVES

This study was undertaken to determine whether quinidine pharmacodynamics are altered in the presence of left ventricular dysfunction.

BACKGROUND

Left ventricular function is an independent predictor of antiarrhythmic drug efficacy. However, the effects of left ventricular dysfunction on the pharmacodynamics of antiarrhythmic drugs have not been studied extensively.

METHODS

Signal-averaged electrocardiograms were obtained and quinidine plasma concentrations measured during 24-h quinidine washout in 22 patients.

RESULTS

Linear quinidine concentration-effect relations were observed for QRS and QT intervals corrected for heart rate. The slopes of the concentration-effect relation describing changes in the corrected QT (QTc) interval were significantly higher in the group with left ventricular ejection fraction > or = 0.35 ([mean +/- SD] 29.5 +/- 11.2 ms/micrograms per ml) than in the group with a low left ventricular ejection fraction (15.7 +/- 9.7 ms/micrograms per ml, p = 0.001). The QRS concentration-effect relations were not different in the two groups. A significant linear correlation was observed between the slopes of the concentration-effect relations describing changes in QTc intervals and left ventricular ejection fraction (r = 0.7, p < 0.001). Nineteen patients with inducible ventricular tachycardia underwent serial electrophysiologic studies for evaluation of quinidine efficacy. Ventricular tachycardia could not be induced during quinidine therapy in eight patients. The slopes of the quinidine concentration-effect relations for QTc intervals were significantly higher in quinidine responders than in nonresponders (p < 0.05).

CONCLUSIONS

The effects of quinidine on ventricular repolarization are linearly related to left ventricular ejection fraction. Quinidine concentration-effect relations describing ventricular repolarization are associated with antiarrhythmic efficacy in patients with ventricular tachycardia.

Moricizine concentration to guide arrhythmia treatment: with attention to elderly patients

To test the relationship between plasma moricizine concentration and the electrocardiogram (ECG) and arrhythmia suppression, 17 symptomatic cardiac patients with 30 or more ventricular premature complexes per hour were studied. Seven patients were mature adults, less than 60 years of age; and ten were elderly adults, more than 60 years of age. During steady-state moricizine therapy, patients had plasma moricizine concentration determined over a dosing interval, and had standard 12-lead ECG and a 24-hour ambulatory ECG recorded. The mean moricizine dose was 215 +/- 29 mg every 8 hours; mean maximal moricizine concentration was 1.4 +/- 0.84 micrograms/ml; and mean t1/2 beta was 1.5 +/- 0.7 hours. Baseline age-related differences were found, including prolonged electrocardiographic intervals (PR and QRS) (P < .05), increased ventricular arrhythmias (P < .05), and reduction in creatinine clearance (P < .05) in the elderly. Compared with pretreatment values, PR (P < .05) and QRS (P < .05) prolongation was observed, and was more marked in elderly patients. Over a dosing interval, there were dynamic changes on the ECG that paralleled plasma moricizine concentration; that is, peak and nadir intact moricizine concentration occurred simultaneously with ECG changes: QRS and JTc prolonged (P < .05), and PR prolongation approached significance (P = 0.09). Suppression of ventricular premature complexes of 80% or more occurred in 15 patients, and ventricular tachycardia was abolished in 10 of 12 patients. Probit analysis revealed that the therapeutic antiarrhythmic concentration ranged from 0.20 to 3.6 micrograms/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

Comparison of spectral temporal mapping to the time domain signal-averaged electrocardiogram in normal subjects and in patients with coronary artery disease and sustained ventricular tachycardia

Spectral temporal mapping is a new form of analysis for signal-averaged electrocardiography, which has the goal of improving the sensitivity and specificity of traditional time domain analysis. Our objective in this study was to determine the effectiveness of one form of spectral temporal mapping, in the face of conflicting results that have so far been reported with this approach. We prospectively performed both spectral temporal mapping and time domain analysis on 50 patients with a history of coronary artery disease and inducible sustained monomorphic ventricular tachycardia (Group 1) and on 25 normal subjects with normal electrocardiograms and no history of heart disease (Group 2). We found that for the 40 Group 1 patients without bundle branch block (Group 1A), the sensitivity of spectral temporal mapping was lower than that for time domain analysis (45% vs 80%, P < 0.005). The results of spectral temporal mapping for Group 1A patients were similar to that for all of Group 1. The sensitivity of spectral temporal mapping was 60% (n = 10) for patients with bundle branch block (Group 1B). The specificity noted in Group 2 was 88% by each means of analysis; however, no one in Group 2 had an abnormal finding by time domain and spectral temporal mapping. Attempts to optimize the criteria for an abnormal spectral analysis did not identify criteria that were superior to those currently in use. We conclude that spectral temporal mapping using Haberl's method is inferior to time domain analysis in identifying patients with sustained ventricular tachycardia, but may be of value in conjunction with the traditional approach in identifying normal subjects.

Nonsustained ventricular tachycardia: identification and management of high-risk patients

NSVT is common in normal persons and in patients with a variety of heart diseases. When present in patients with coronary artery disease, particularly after a recent myocardial infarction, it is associated with an increased risk of sudden and nonsudden cardiac death. However, its prognostic significance in patients with nonischemic heart disease, with the possible exception of hypertrophic cardiomyopathy, remains controversial. In patients with coronary artery disease, certain diagnostic tools (e.g., determination of left ventricular function. PVS) help to identify low- and high-risk patients who may or may not benefit from antiarrhythmic treatment. There is no consensus at this point as to the best approach for identifying and treating high-risk patients. Ongoing clinical trials should provide important information on the roles of signal-averaged ECGs and PVS in the management of patients with NSVT and coronary artery disease. In the meantime, treatment should be individualized for each patient. beta-Blockers should probably be the first line of therapy to control symptoms. Asymptomatic potentially high-risk patients (i.e., those with LVEF < 40%) should be referred for enrollment in randomized controlled studies.

Modification of late potentials by intracoronary ethanol infusion

Antiarrhythmic drugs have no consistent effects on the signal-averaged electrocardiogram (ECG) while successful surgical ablation of ventricular tachycardia is known to abolish late potentials. Ten patients with prior myocardial infarction had successful ablation of recurrent sustained ventricular tachycardia by selective ethanol infusion into a small coronary vessel supplying the tachycardia origin. Signal-averaged ECGs were performed before and after initially successful ablation in patients without pacemaker dependence or intraventricular conduction delay to assess the effects on late potentials and to determine if the signal-averaged ECG could predict ventricular tachycardia recurrence. Only four of ten patients were eligible for study and all four had late potentials prior to ethanol ablation. Late potentials were abolished in one patient who has not had an arrhythmia recurrence in 25 months. One patient with sudden death and another patient with ventricular tachycardia recurrence had persistent late potentials post procedure that were modified by a reduction in terminal voltage and lengthening of terminal low amplitude signal. The fourth patient who receives chronic amiodarone had no arrhythmia recurrence in spite of persistent but modified late potentials. Thus, the abolition of late potentials after ethanol ablation may predict freedom from arrhythmia recurrence.

The effects of type I antiarrhythmic drugs on the signal-averaged electrocardiogram in patients with malignant ventricular arrhythmias

The effects of type I antiarrhythmic drugs on the signal-averaged electrocardiogram (SAECG) were analyzed in 58 patients with inducible sustained monomorphic ventricular tachycardia. SAECGs were acquired before and after drug therapy. A total of 99 drug trials were analyzed (mean 1.7 per patient). Analysis of temporal domain parameters included the duration of the QRS complex (QRSD), the high frequency total duration of the filtered QRS complex (HFTD), the duration of the signal under 40 microV (D40), initial QRS (HFTD minus D40), and the root mean square amplitude (RMSA) of the terminal 40 msec of the QRS signal. Changes in temporal parameters failed to predict drug efficacy. There were, however, type-specific drug effects on the SAECG. With the exception of type IB drugs, all drugs increased the QRSD, HFTD, and D40. Type IC drugs caused more prolongation of the QRSD and HFTD than type IA, IB, and the combination of IA+IB drugs. Prolongation of the HFTD was related to prolongation of the late potential and the initial portion of the QRS complex. A preferential effect of these drugs on the late potential was not observed. Type IC drugs also caused more prolongation of ventricular tachycardia cycle length than type IA or IB drugs. However, the increase in ventricular tachycardia cycle length did not correlate with a change in the SAECG. In summary, type I antiarrhythmic drugs cause a global slowing of ventricular activation. Although analysis of the SAECG following drug therapy was not useful for predicting drug efficacy, drug induced changes in the SAECG may be helpful for categorizing antiarrhythmic agents.